AIM ImmunoTech Inc. filings document an immuno-pharma issuer centered on Ampligen (rintatolimod) and its public-company financing, clinical and governance disclosures. Recent 8-K reports cover material agreements, Regulation FD clinical updates for the DURIPANC pancreatic cancer study, amendments to equity distribution arrangements, warrant notices, and operating and financial results.
Registration statements and related exhibits disclose rights-offering terms, Series G Convertible Preferred Stock, common stock purchase warrants, beneficial-ownership limits, warrant agency arrangements, and shelf or at-the-market equity issuance mechanics. The filings also address risk factors, shareholder-rights modifications, corporate-governance items and capital-structure changes relevant to AIM's research-and-development drug business.
AIM ImmunoTech Inc. (AIM) entered into two exchange agreements with Streeterville Capital, LLC between September 8 and September 9, 2026, using corresponding partitioned promissory notes tied to a previously issued promissory note dated November 18, 2025. Under these agreements, approximately $400,000 of debt was converted into 1,749,434 shares of common stock at an average conversion price of about $0.228 per share. Stockholders had previously approved the conversion or other satisfaction of the promissory note pursuant to NYSE American Company Guide Sections 713(a) and 713(b) at a special meeting held on July 15, 2026. The exchange shares were or will be issued in reliance on the Section 3(a)(9) exemption from registration under the Securities Act of 1933.
AIM ImmunoTech Inc. (AIM) reports that on September 3 and 4, 2026 it entered into two exchange agreements with Streeterville Capital, LLC tied to an existing Promissory Note dated November 18, 2025. Under these agreements and related partitioned promissory notes, approximately $450,000 of debt was converted into 1,921,441 shares of common stock at an average conversion price of about $0.234 per share. Stockholders had previously approved the conversion or other satisfaction of this note at a special meeting on July 15, 2026 pursuant to NYSE American Company Guide Sections 713(a) and 713(b). The exchange shares were or will be issued in reliance on the Section 3(a)(9) exemption from Securities Act registration.
AIM ImmunoTech Inc. (AIM) entered into five exchange agreements with Streeterville Capital, LLC between August 31 and September 3, 2026 to address an existing promissory note dated February 16, 2024. Under these agreements, approximately $1,224,341 of the note was converted into 5,065,840 shares of common stock.
The exchanges were effected via corresponding partitioned promissory notes at an average conversion price of about $0.24 per share, and as of September 3, 2026 the promissory note was satisfied in full with no remaining amounts owed. Stockholders had previously approved the conversion or other satisfaction of this note on July 15, 2026 pursuant to NYSE American Company Guide Sections 713(a) and 713(b). The exchange shares were or will be issued under the Securities Act exemption in Section 3(a)(9) for exchanges with an existing security holder where no commission or other remuneration is paid for soliciting the exchange.
AIM ImmunoTech Inc. reported that CEO Thomas K. Equels authored a sponsor-supplied article on Breaking Defense titled “Biodefense is force protection: Ready today, prepared for tomorrow.” The piece argues that biodefense should be treated as military force protection and highlights the company’s drug Ampligen (rintatolimod) as a potential broad-spectrum early-onset and/or prophylactic antiviral for Ebola virus disease and coronaviruses, based on government-funded preclinical studies. The article cites 100% survival in one rintatolimod-treated mouse cohort versus 100% mortality in controls in an Ebola model and describes prior preclinical work in SARS-related coronaviruses. AIM emphasizes that these findings are preclinical proof-of-concept, not FDA approval or evidence of clinical efficacy, and includes extensive forward-looking statement and risk-factor cautions.
AIM ImmunoTech Inc. reported second-quarter 2026 results and progress on its lead drug Ampligen in metastatic pancreatic cancer. The company completed patient enrollment and Ampligen dosing in the Phase 2 DURIPANC study combining Ampligen with Imfinzi and engaged Thermo Fisher Scientific’s PPD business to support planned Phase 3 trial design. AIM highlighted prior Dutch Named Patient Program data where Ampligen achieved a median Overall Survival of 34.8 months versus 12.5 months for historical controls in a selected biomarker subset, and anticipates DURIPANC clinical benefit data in Q1 2027 and Overall Survival data in Q3 2027.
Cash and cash equivalents were $9.9 million as of June 30, 2026, compared with approximately $3.0 million as of December 31, 2025, following multiple financing transactions and regaining full NYSE American listing compliance. For Q2 2026, research and development expenses were approximately $589,000 versus $1.2 million a year earlier, while general and administrative expenses rose to about $2.9 million from $1.5 million. Net loss was approximately $(3.8 million), or $(0.43) per share, compared with $(2.8 million), or $(3.68) per share, for Q2 2025. The company is also planning government-focused initiatives to evaluate Ampligen’s antiviral potential against Ebola virus disease.
AIM ImmunoTech Inc., an immuno‑pharma company developing Ampligen and Alferon, reported very limited Q2 2026 revenue of $26 thousand and an operating loss of $3.5 million, compared with a $2.6 million operating loss a year earlier. Net loss for the quarter was $3.8 million, and $6.8 million for the first half of 2026.
Cash and cash equivalents increased to $9.9 million at June 30, 2026 from $3.0 million at December 31, 2025, driven by $14.4 million of net cash provided by equity offerings and warrant exercises in the first six months. Total assets were $12.7 million, with stockholders’ equity improving to $7.7 million from a $9.8 million deficit.
Management states that recurring losses and operating cash outflows of $7.3 million for the first half raise substantial doubt about the company’s ability to continue as a going concern for at least one year. AIM continues to advance Ampligen, including a fully enrolled Phase 2 DURIPANC trial in metastatic pancreatic cancer and preparatory work for a potential Phase 3 study.
AIM ImmunoTech Inc. entered into a Proposal Agreement with Sterling Pharma Solutions on July 31, 2026. Under this arrangement, Sterling will manufacture additional batches of the polynucleotide drug substances PolyI and Poly C12U and transfer associated test methods at its Dudley, UK facility. These materials serve as polymer precursors for producing the drug Ampligen.
The estimated cost to AIM is approximately $1.5 million, payable over 12 months. AIM plans to use the manufactured product in ongoing and future clinical trials, including potentially a Phase 3 clinical trial for metastatic pancreatic cancer.
AIM also outlined timing requirements for stockholders wishing to nominate directors or bring other business at the 2026 annual meeting outside Rule 14a-8. Notices must be received between August 18, 2026 and 5:00 p.m. local time on September 17, 2026, with a separate Rule 14a-19 universal proxy notice due by October 19, 2026.
AIM ImmunoTech Inc. is terminating its Equity Distribution Agreement with Maxim Group LLC, which allowed sales of common stock in an at the market offering under Rule 415. Notice of mutual termination was given on July 31, 2026, and the termination is effective August 15, 2026. The company will not incur any termination penalties.
Under this program, from April 1, 2025 to July 31, 2026, AIM ImmunoTech sold 3,200,736 shares of common stock for aggregate gross proceeds of approximately $2.8 million. The company does not intend to issue or sell any additional shares under the Agreement before termination, and after termination it may not offer or sell any additional shares under that Agreement or the related prospectus and prospectus supplement.
AIM ImmunoTech Inc. held a Special Meeting of Stockholders on July 15, 2026, with 10,671,690 of 27,724,245 common shares represented, or 38.5%, exceeding the 33 and 1/3% quorum requirement. Stockholders approved several proposals tied to future equity issuance and capital structure flexibility.
They authorized, for NYSE American Company Guide Sections 713(a) and 713(b) compliance, the issuance of more than 19.99% of outstanding common stock upon exercise of Class H, Class I and Class J common stock purchase warrants, and upon conversion or other satisfaction of promissory notes dated February 16, 2024 and November 18, 2025. Stockholders also approved amendments permitting the Board, at its option, to implement a reverse stock split at a ratio of up to 1-for-25, and approved the ability to adjourn the Special Meeting to a later date or time to solicit additional proxies if necessary.
AIM ImmunoTech Inc. has called a virtual special stockholder meeting on July 15, 2026 to approve several financing-related actions and a potential reverse stock split. Holders of 27,724,245 shares of common stock as of June 15, 2026 may vote.
Stockholders are asked to approve issuances of more than 19.99% of outstanding shares tied to Class H, I and J warrants and to conversions of two promissory notes, in each case to comply with NYSE American Company Guide Sections 713(a) and 713(b). The company discloses that full cash exercises of these warrants could bring in additional gross proceeds of about $8.9 million (Class H), $4.9 million (Class I) and $5.3 million (Class J).
Another proposal would authorize the board, at its option, to implement a reverse stock split at a ratio of up to 1-for-25. The proxy explains that existing cash and investments are not expected to fund 12 months of operations and states that failure to raise additional capital in the very near term could force substantial cutbacks or even a voluntary bankruptcy filing. The board unanimously recommends voting “FOR” all seven proposals.